Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Carboplatin and Paclitaxel in Metastatic Head and Neck Squamous Cell Carcinoma
NCT04858269Phase 2Active, not recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2021
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, carboplatin, Paclitaxel Micelles for Injection in head and neck squamous cell carcinoma (HNSCC), sponsored by Wake Forest University Health Sciences. Started May 2021; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04858269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04858269.